Chair’s Opening Remarks
February 1, 2017 • 8:15 am
Using Audits and Risk Evaluation to Assess the State of Your Compliance Program
February 1, 2017 • 10:45 am
Aggregate Spend Laws and Related Legislation Concerning Interactions with Health Care Professionals and Their Impact on Compliance
January 31, 2017 • 11:45 am
Life Sciences Advertising and Promotion and Social Media Usage Compliance 1.0
January 31, 2017 • 2:45 pm
Building and Structuring a Compliance Infrastructure for Life Sciences Companies: Legalities and Ethics
January 31, 2017 • 9:30 am
Managing Compliance Risks in Clinical Trials and R&D
February 1, 2017 • 9:45 am
Key Privacy Considerations for Any Life Sciences Compliance Program
January 31, 2017 • 5:00 pm
Understanding the Importance of cGMP and Quality Systems Compliance in an Era of Heightened FDA Enforcement
January 31, 2017 • 2:00 pm
Government Enforcement Trends that Dictate Compliance Protocols: Understanding How the False Claims Act and Anti- Kickback Laws Have Shaped Life Sciences Compliance Programs
January 31, 2017 • 10:45 am
Compliance Needs Assessment Strategies: Using Objective Criteria to Evaluate Subjective Needs
January 31, 2017 • 8:30 am
Life Sciences Advertising and Promotion and Social Media Usage Compliance 2.0 – Exploring the Dangers of Off Label Use
January 31, 2017 • 4:00 pm
Medical Affairs: Understanding Its Role in Your Compliance Program
February 1, 2017 • 8:30 am
Price Reporting and Reimbursement Compliance
February 1, 2017 • 11:30 am
Receive exclusive discounts, offers and agenda updates directly to your inbox.
